PCM Encore’s Aurinia Pharmaceuticals AUPH Stock Holding History

PCM Encore’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$457K	Hold	26,917	–	–	0.08%	230
2026 Q1	$399K	Hold	26,917	–	–	0.08%	247
2025 Q4	$429K	Buy	+26,917	New	+$382K	0.09%	218

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PCM Encore's AUPH Position: Q2 2026 in Review

PCM Encore held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 26,917 shares worth $457K. The position accounts for 0.08% of the portfolio, ranked #230.

PCM Encore first reported a position in AUPH in Q4 2025 and has held it in 3 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

PCM Encore held 26,917 shares of Aurinia Pharmaceuticals worth $457K as of Q2 2026.
PCM Encore left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
Aurinia Pharmaceuticals made up 0.08% of PCM Encore's portfolio in Q2 2026, its #230 holding.
PCM Encore first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on PCM Encore's 13F filing for Q2 2026, filed 11 Aug 2026.